Ausgabe 5/2018
Inhalt (7 Artikel)
Myelodysplastic Syndromes (M Savona, Section Editor)
Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia
Aziz Nazha, Mrinal M. Patnaik
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Updates on Circulating Tumor DNA Assessment in Lymphoma
Justin M. Darrah, Alex F. Herrera
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma
Joanna Rhodes, Daniel J. Landsburg
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Jennifer K. Lue, Jennifer E. Amengual
CART and Immunotherapy (M Ruella, Section Editor)
Strategies for Predicting Response to Checkpoint Inhibitors
Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub
Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors)
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Katherine C. Pehlivan, Brynn B. Duncan, Daniel W. Lee
Myeloproliferative Neoplasms (B Stein, Section Editor)
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
John H. Baird, Jason Gotlib